上海后花园KEQ

first_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. @Pharmalot Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of cherries and chocolate — and get started. Meanwhile, do keep us in mind if you hear anything interesting. Have a smashing day …GlaxoSmithKline (GSK) hopes to revamp drug discovery with a $300 million bet on genetics by buying a stake in 23andMe, Reuters writes. The deal provides the drug maker with exclusive access to the vast DNA database it hopes will help unlock new treatments for a range of diseases. 23andMe, which is backed by Google, has more than 5 million customers, 80 percent of whom have opted in to participate in research; it also has a trove of information about the links between genes and disease. The first project will focus on an experimental Glaxo pill for Parkinson’s disease. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. [email protected] GET STARTED Log In | Learn More By Ed Silverman July 25, 2018 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalot center_img Pharmalittle: Glaxo buys a $300 million stake in 23andMe; CF patients sue for coverage Alex Hogan/STAT What’s included? Ed Silverman Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What is it? About the Author Reprints Tags drug pricingfinancejobslegalopioidspharmaceuticalsSTAT+last_img read more

Read More